Research ArticleArticle
A Strategy for Assessing Potential Drug-Drug Interactions of a Concomitant Agent against a Drug Absorbed via an Intestinal Transporter in Humans
Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa and Jun-ichi Yamaguchi
Drug Metabolism and Disposition September 2014, 42 (9) 1456-1465; DOI: https://doi.org/10.1124/dmd.114.058305
Akiko Mizuno-Yasuhira
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Yasuhiro Nakai
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Emi Gunji
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Saeko Uchida
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Teisuke Takahashi
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Kohnosuke Kinoshita
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Shigeji Jingu
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Soichi Sakai
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Yoshishige Samukawa
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Jun-ichi Yamaguchi
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Prediction of Transporter-Mediated DDI Using a Dynamic Model
Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa and Jun-ichi Yamaguchi
Drug Metabolism and Disposition September 1, 2014, 42 (9) 1456-1465; DOI: https://doi.org/10.1124/dmd.114.058305
Research ArticleArticle
Prediction of Transporter-Mediated DDI Using a Dynamic Model
Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa and Jun-ichi Yamaguchi
Drug Metabolism and Disposition September 1, 2014, 42 (9) 1456-1465; DOI: https://doi.org/10.1124/dmd.114.058305
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement